Novartis: Ovarian cancer drug disappoints in trial

Novartis: Ovarian cancer drug disappoints in trial
(AP) — Swiss drug maker Novartis AG said Thursday it won’t ask regulators for permission to market a new ovarian cancer drug after a late-stage trial proved disappointing.

Read more on PhysOrg

More Meth Drug Addiction Info:

• Evista taxotere and ovarian cancer | Kolioasa.msk.ru med blog
• Ovarian Cancer ? Types With Treatment | Geo Blog
• Novartis: Ovarian cancer drug disappoints in trial | TechOat.com
• A Big Thank You to the Worldwide ERC Foundation! | Ovarian Cancer …
• Pegylated Liposomal Doxorubicin and Carboplatin Compared With …
• Policy Update | Ovarian Cancer National Alliance
• Novartis ovarian cancer drug filings won't proceed – Latest Cancer …
• AstraZeneca's Colon Cancer Drug Recentin Fails To Meet Primary …
• Mixed News For Novartis' Pipeline | Daily Markets
• Ovarian Cancer Alternative Treatment | Cancer News Today